AI Diagnostics for Pharma
Next-generation AI Dx
AI diagnostics unlock significant value for pharma
AI Digital Pathology Diagnostics
Owkin Dx expedite and improve diagnosis in clinical trials and clinical routine
Next-generation AI diagnostics
Fast, seamless access to a vast academic data network, providing high-quality patient data for training, testing, and validation in real-world settings.
Harness the power of advanced AI techniques, including representation learning, transfer learning, and foundation models, for best-in-class generalizable solutions.
product expertise
Navigate complex regulatory landscapes with confidence, supported by our proven expertise and CE-IVD-approved diagnostic products.
A strong network of distribution partners to ensure broad market coverage.
Benefit from ‘generalizable by design’ platform-agnostic solutions.
Trusted by pharma
We are delivering value for our pharma partners
gBRCA not routinely tested in all breast cancers.
Astrazeneca and Owkin partner to develop an AI gBRCA screening solution for breast cancer.
MSI not routinely tested in all cancers.
MSD and Owkin partner to develop a biomarker screening tool to improve testing rates for MSI-H in endometrial, gastric, small intestinal and biliary cancers.
Our Dx products in development
Citations
- Clinical development success rates 2011-2021: Statista 2023, 8% vs 16% phase 1 to approval success rate
- Thomas, D. W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., & Hay, M. (2016). Clinical Development Success Rates 2006–2015
- https://society.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/2022-Biomarker-Tests-Cancer-Care-Brief.pdf; https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/12/12/the-cost-of-biomarker-testing-moving-from-support-based-to-sustainable-solutions